nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.04.2013 | Original article

Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk

Planning study in esophageal carcinoma

verfasst von: K. Fakhrian, MD, Vice Chair, M. Oechsner, PhD, S. Kampfer, T. Schuster, PhD, M. Molls, MD, H. Geinitz, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this work was to investigate the potential of advanced radiation techniques in dose escalation in the radiotherapy (RT) for the treatment of esophageal carcinoma.

Methods

A total of 15 locally advanced esophageal cancer (LAEC) patients were selected for the present study. For all 15 patients, we created a 3D conformal RT plan (3D-45) with 45 Gy in fractions of 1.8 Gy to the planning target volume (PTV1), which we usually use to employ in the neoadjuvant treatment of LAEC. Additionally, a 3D boost (as in the primary RT of LAEC) was calculated with 9 Gy in fractions of 1.8 Gy to the boost volume (PTV2) (Dmean) to a total dose of 54 Gy (3D-54 Gy), which we routinely use for the definitive treatment of LAEC. Three plans with a simultaneous integrated boost (SIB) were then calculated for each patient: sliding window intensity-modulated radiotherapy (IMRT-SIB), volumetric modulated arc therapy (VMAT-SIB), and helical tomotherapy (HT-SIB). For the SIB plans, the requirement was that 95 % of the PTV1 receive ≥ 100 % of the prescription dose (45 Gy in fractions of 1.8 Gy, D95) and the PTV2 was dose escalated to 52.5 Gy in fractions of 2.1 Gy (D95).

Results

The median PTV2 dose for 3D-45, 3D-54, HT-SIB, VMAT-SIB, and IMRT-SIB was 45, 55, 54, 56, and 55 Gy, respectively. Therefore, the dose to PTV2 in the SIB plans was comparable to the 3D-54 plan. The lung dose in the SIB plans was in the range of the standard 3D-45, which is applied for neoadjuvant radiotherapy. The mean lung dose for the same plans was 13, 15, 12, 12, and 13 Gy, respectively. The V5 lung volumes were 71, 74, 79, 75, and 73 %, respectively. The V20 lung volumes were 20, 25, 16, 18, and 19 %, respectively.

Conclusion

New treatment planning techniques enable higher doses to be delivered for neoadjuvant radiotherapy of LAEC without a significant increase in the delivered dose to the organs at risk. Clinical investigations are warranted to study the clinical safety and feasibility of applying higher doses through advanced techniques in the neoadjuvant treatment of LAEC.

Lee JL, Park SI, Kim SB et al (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947–954PubMedCrossRef

Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234PubMedCrossRef

Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal acenocarcinoma. N Engl J Med 335:462–467PubMedCrossRef

Kranzfelder M, Schuster T, Geinitz H et al (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768–783PubMedCrossRef

Pöttgen C, Stuschke M (2012) Radiotherapy versus surgery within multimodality protocols for esophageal cancer—A meta-analysis of the randomized trials. Cancer Treat Rev 38:599–604PubMedCrossRef

Koki Y, Ishikawa O, Takashi K et al (2005) Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg 29:700–705CrossRef

Welsh J, Palmer MB, Ajani JA et al (2012) Esophageal cancer dose escalation using a imultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82:468–474PubMedCrossRef

Settle SH, Bucci MK, Palmer MB et al (2008) PET/CT fusion with treatment planning CT (TP CT) shows predominant pattern of locoregional failure in esophageal patients treated with chemoradiation (CRT) is in GTV. Int J Radiat Oncol Biol Phys 72:S72–S73CrossRef

Minsky B, Pajak T, Ginsberg R et al (2002) INT0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer high-dose versus standard dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRef

10.

D’Journo XB, Michelet P, Dahan L et al (2008) Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg 33:1117–1123CrossRef

11.

Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17):1623–1627PubMedCrossRef

12.

Nutting CM, Bedford JL, Cosgrove VP, Tait DM et al (2005) A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 61:157–163CrossRef

13.

Fakhrian K, Heilmann J, Schuster T et al (2012) Primary radiotherapy with or without chemotherapy in non-metastatic esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus 25:256–262PubMedCrossRef

14.

Sun SP, Liu YZ, Ye T, Zhang W et al (2006) Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity. World J Gastroenterol 12:7047–7050PubMed

15.

Nishimura Y, Ono K, Tsutsui K (1994) Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys 30:1099–1105PubMedCrossRef

16.

Shirai K, Tamaki Y, Kitamoto Y et al (2011) Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 80:1002–1007PubMedCrossRef

17.

Miyata H, Yamasaki M, Takiguchi S et al (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 100:442–446PubMedCrossRef

18.

Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ (2007) Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 94:1059–1066PubMedCrossRef

19.

Ariga H, Nemoto K, Miyazaki S et al (2009) Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of esophagus Int J Radiat Oncol Biol Phys 75:348–356

20.

Wilson KS, Lim JT (2000) Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. Radiother Oncol 54:129–134PubMedCrossRef

21.

Bosset JF, Gignoux M, Triboulet JP et al (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337:161–167PubMedCrossRef

22.

Samel S, Hofheinz R, Hundt A et al (2001) Neoadjuvant radiochemotherapy of adenocarcinoma of the oesophagogastric junction. Onkologie 24:278–282PubMedCrossRef

23.

Lee HK, Vaporciyan AA, Cox JD et al (2003) Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 57:1317–1322PubMedCrossRef

24.

Wang SL, Liao Z, Vaporciyan AA et al (2006) Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64:692–699PubMedCrossRef

25.

Tucker SL, Liu HH, Wang S et al (2006) Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66:754–761PubMedCrossRef

26.

Adelstein DJ, Rice TW, Becker M et al (1997) Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80:1011–1020PubMedCrossRef

27.

Valentí V, Hernández-Lizoain JL, Marínez-Regueira F (2011) Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients: multidisciplinary approach. Clin Transl Oncol 13:899–903PubMedCrossRef

28.

Schieman C, Wigle DA, Deschamps C (2012) Patterns of operative mortality following esophagectomy. Dis Esophagus 25:645–651PubMedCrossRef

29.

Whooley BP, Law S, Murthy SC (2001) Analysis of reduced death and complication rates after esophageal resection. Ann Surg 233:338–344PubMedCrossRef

30.

Dähn D, Martell J, Vorwerk H et al (2010) Influence of irradiated lung volumes on perioperative morbidity and mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 77:44–52PubMedCrossRef

31.

Boshier PR, Anderson O, Hanna GB (2011) Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg 254:894–906PubMedCrossRef

32.

Hulscher JB, Sandick JW van, Boer AG de (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662–1669PubMedCrossRef

33.

Marks LB, Bentzen SM, Deasy JO (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76(3 Suppl):70–76CrossRef

34.

Subramaniam S, Thirumalaiswamy S, Srinivas C et al (2012) Chest wall radiotherapy with volumetric modulated arcs and the potential role of flattening filter free photon beams. Strahlenther Onkol 188:484–491PubMedCrossRef

35.

Wiehle R, Knippen St, Grosu AL et al (2011) VMAT and step-and-shoot IMRT in head and neck cancer: a comparative plan analysis. Strahlenther Onkol 187:820–825PubMedCrossRef

36.

Mayo CS, Urie MM, Fitzgerald TJ, Ding L et al (2008) Hybrid IMRT for treatment of cancers of the lung and esophagus. Int J Radiat Oncol Biol Phys 71:1408–1418PubMedCrossRef

37.

Chen YJ, Liu A, Han C et al (2007) Helical tomotherapy for radiotherapy in esophageal cancer: a preferred plan with better conformal target coverage and more homogeneous dose distribution. Med Dosim 32:166–171PubMedCrossRef

38.

Uhl M, Sterzing F, Habl G et al (2012) Breast cancer and funnel chest comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum. Strahlenther Onkol 188:127–135PubMedCrossRef

39.

Fakhrian K, Gamisch N,·Schuster T et al (2012) Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 188:136–142PubMedCrossRef

40.

Semrau R, Herzog SL, Vallböhmer D et al (2012) Radiotherapy in elderly patients with inoperable esophageal cancer Is there a benefit? Strahlenther Onkol 188:226–234PubMedCrossRef

Titel: Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk
Planning study in esophageal carcinoma
verfasst von: K. Fakhrian, MD, Vice Chair
M. Oechsner, PhD
S. Kampfer
T. Schuster, PhD
M. Molls, MD
H. Geinitz, MD
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0297-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk

Planning study in esophageal carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Konventionell fraktionierte postoperative Radiotherapie bis 50,4 Gy für progrediente „Low-Grade“-Gliome beim Erwachsenen weiterhin therapeutischer Standard

Radiotherapy for calcaneodynia

Proton beam therapy for malignancy in Bloom syndrome

Set-up uncertainty during breast radiotherapy

Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments

Professor Árpád Mayer zum 70. Geburtstag

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie